title: Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Alvarez-Twose
authors.affiliation: Hematology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Martínez-Barranco
authors.affiliation: Division of Hematology, Department of Medicine, Stanford University School of Medical/Stanford Cancer Institute, Stanford, CA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Gotlib
authors.affiliation: Servicio General de Citometría (NUCLEUS), Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
authors.forename: A
authors.initials: A
authors.lastname: García-Montero
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Morgado
authors.affiliation: Servicio General de Citometría (NUCLEUS), Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Jara-Acevedo
authors.affiliation: Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Merker
authors.affiliation: Hematology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
authors.forename: F J
authors.initials: FJ
authors.lastname: Peñalver
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Matito
authors.affiliation: Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Hou
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Sánchez-Muñoz
authors.affiliation: Servicio General de Citometría (NUCLEUS), Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Mayado
authors.affiliation: Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Mollejo
authors.affiliation: Servicio General de Citometría (NUCLEUS), Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Escribano
authors.affiliation: Servicio General de Citometría (NUCLEUS), Centro de Investigación del Cáncer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Orfao
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D007946:Leukemia, Mast-Cell / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000079982:Gemtuzumab